First-in-human study of NTSR1-targeted imaging in prostate cancer shows promise
[18F]-AlF-NOTA-neurotensin shows potential as an NTSR1-targeted radiotracer for prostate cancer imaging.
| Drug | MOA / Company | Stage |
|---|---|---|
| Oncology | Novartis | Lead |
Focal Asset
Oncology
Company
Novartis
Indication
prostate cancer
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The emergence of [18F]-AlF-NOTA-neurotensin as a potential alternative to [68Ga]Ga-PSMA-617 could significantly alter imaging strategies in prostate cancer. This development may lead to a shift in market dynamics, necessitating close monitoring by pharma strategy teams.
Recommended action
Humanexa recommends Monitor: Monitoring is recommended to assess the ongoing trial results and the comparative efficacy of [18F]-AlF-NOTA-neurotensin against [68Ga]Ga-PSMA-617, as this will inform strategic decisions moving forward.
Analysis
Monitor further trial results and comparative efficacy against [68Ga]Ga-PSMA-617.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.